News

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories

By Italia on November 10 2014

RUTHERFORD, N.J., November 10, 2014 (GLOBE NEWSWIRE) – Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014. Third quarter revenue of $3.22 million – overall revenue growth of ~90% over the same quarter of 2013, including 159% revenue growth in Biopharma […]

Continue Reading

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10

By Italia on October 30 2014

RUTHERFORD, NJ – October 30, 2014 – Cancer Genetics, Inc. (NasdaqCM: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014.  The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern […]

Continue Reading

Cancer Genetics Inc Granted Patent for Genomic Probe Set Used in Proprietary Test For Cervical and Other HPV-Associated Cancers

By Italia on October 21 2014

> Issuance of patent 8,865,882 covers four probe set used in CGI’s proprietary FISH-based HPV-Associated Cancer Test (FHACT®) > FHACT® cervical cancer detection test has potential application for more than 2 million patients per year in the United States RUTHERFORD, N.J., October 21, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), […]

Continue Reading

Cancer Genetics’ Proprietary IVD for Cervical Cancer, FHACT®, Receives CE Mark

By Italia on September 2 2014

> CE marking allows CGI’s DNA-FISH Probe, FHACT®, to be widely marketed in European Economic Area, which covers 31 countries RUTHERFORD, N.J., September 02, 2014 – Cancer Genetics, Inc. (Nasdaq; CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT®) has received the CE […]

Continue Reading

Cancer Genetics’ Proprietary Genomic Diagnostic Tests Added to National Institutes of Health’s Genetic Testing Registry

By Jamie on August 29 2014

Online database allows clinicians and patients to search for genetic and genomic tests by disease state Increases access to information about and awareness of Cancer Genetics’ proprietary diagnostic tests RUTHERFORD, N.J., Aug. 27, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that the National […]

Continue Reading

Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma

By Jamie on August 29 2014

Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin’s lymphoma Results of study will be optimized by CGI to validate and enhance their proprietary genomic panel for DLBCL RUTHERFORD, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, and […]

Continue Reading

Cancer Genetics, Inc. Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL)

By Italia on August 4 2014

CGI’s Proprietary Genomic Panel for Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Is Now Licensed to Report out Risk Stratification of Patients into Three Distinct Groups CGI’s proprietary genomic test has been CLIA and NYS licensed to stratify CLL and SLL patient into three distinct outcome groups: favorable, […]

Continue Reading

Cancer Genetics to Acquire Gentris Corporation, a Global Leader in Pharmacogenomic Profiling for Therapeutic Development, Companion Diagnostics & Clinical Trials

By Jamie on June 23 2014

Acquisition Will Provide Comprehensive Capabilities in Genomic Profiling for Clinical Trials, Pharmacogenomics, and Significantly Expand Cancer Genetics’ Biotech and Pharmaceutical Client Base RUTHERFORD, N.J., June 23, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, today announced the signing of a non-binding Letter of […]

Continue Reading

Cancer Genetics, Inc. Announces Partnership With AstraZeneca to Provide Biomarker & Molecular Based Testing

By Jamie on June 9 2014

Agreement Expands Reach of Cancer Genetics’ Molecular Diagnostic & Biomarker Services Collaboration Will Focus On Select Oncology Categories & Trials RUTHERFORD, N.J., June 9, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, has been selected by AstraZeneca CAMCAR, S.A., (“AZ-CAMCAR”), a division of multinational pharmaceutical […]

Continue Reading

Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab to Provide Great Availability of FHACT®, a Non-Invasive, Genomic Test to Guide the Detection and Management of Cervical Cancer

By Jamie on June 3 2014

Collaboration With PathAdvantage Introduces Precision Testing for Cervical Cancer Into The Rapidly Growing Metro Dallas and North Texas Market PathAdvantge Will Incorporate the Genomic Test as Part of Its Comprehensive Focus on Gynecological Cancers RUTHERFORD, N.J., June 3, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) a DNA-based diagnostics company focused on developing genomic-based oncology […]

Continue Reading